Bacillus subtilis HU58 and Bacillus coagulans SC208 Probiotics Reduced the Effects of Antibiotic-Induced Gut Microbiome Dysbiosis in An M-SHIME® Model

Massimo Marzorati; Pieter Van den Abbeele; Sarah S Bubeck; Thomas Bayne; Kiran Krishnan; Aicacia Young; Dilip Mehta; Anselm DeSouza

doi:10.3390/microorganisms8071028

Bacillus subtilis HU58 and Bacillus coagulans SC208 Probiotics Reduced the Effects of Antibiotic-Induced Gut Microbiome Dysbiosis in An M-SHIME^® Model

Microorganisms. 2020 Jul 11;8(7):1028. doi: 10.3390/microorganisms8071028.

Authors

Massimo Marzorati^{1

2}, Pieter Van den Abbeele², Sarah S Bubeck³, Thomas Bayne⁴, Kiran Krishnan⁴, Aicacia Young⁴, Dilip Mehta⁵, Anselm DeSouza⁵

Affiliations

¹ Center for Microbial Ecology and Technology (CMET), Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium.
² ProDigest, Technologiepark 82, 9052 Zwijnaarde, Belgium.
³ Bubeck Scientific, 194 Rainbow Drive #9418, Livingston, TX, 77399, USA.
⁴ Microbiome Labs, 101 E Town Pl, Saint Augustine, FL, 92092, USA.
⁵ Synergia Life Sciences, PVT Ltd., Universal majestic, 1503, PL Lokhande Marg, Chembur, Mumbai, Maharashtra 400071, India.

Abstract

Benefits associated with probiotic use have been reported; however, the mechanisms behind these benefits are poorly understood. The effects of a probiotic formulation (MegaDuo™) containing Bacillus coagulans SC208 and Bacillus subtilis HU58 on intestinal permeability and immune markers was assessed using a combination of the in vitro gut model, the mucosal simulator of the human intestinal microbial ecosystem (M-SHIME^®), and an in vitro inflammatory bowel disease-like Caco-2/THP1 co-culture model in both healthy and antibiotic-induced dysbiosis conditions. Established M-SHIME^® proximal colon vessels were treated with/without clindamycin (1 week) and then with/without daily MegaDuo™ treatment (2 weeks). The mucosal and luminal microbial communities were sampled weekly. Suspensions were removed from the proximal colon vessels after 1 and 2 weeks of MegaDuo™ treatment and added to the co-culture system. Transepithelial resistance (membrane barrier function), cytokine/chemokine release, and NFκB activity were then measured. Under conditions of antibiotic-induced dysbiosis, suspensions from MegaDuo™ treated vessels showed reduced gut membrane barrier damage and decreased levels of TNFα and IL-6 compared with suspensions from untreated vessels; no appreciable differences were observed under healthy conditions. MegaDuo™ treatment had no effect on NFκB activity of THP1-Blue™ cells. The potential benefits of MegaDuo™ treatment appeared most evident after 2 weeks of treatment.

Keywords: M-SHIME; dysbiosis; gut barrier; gut inflammation; gut microbiome; immunomodulation; probiotics.